{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:04:50Z","timestamp":1771470290476,"version":"3.50.1"},"reference-count":135,"publisher":"Elsevier","isbn-type":[{"value":"9780120066919","type":"print"}],"license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004]]},"DOI":"10.1016\/s0065-230x(04)91004-4","type":"book-chapter","created":{"date-parts":[[2004,8,27]],"date-time":"2004-08-27T09:04:12Z","timestamp":1093597452000},"page":"137-168","source":"Crossref","is-referenced-by-count":389,"title":["Histone Deacetylase Inhibitors"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0001","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0092-8674(02)01077-2","article-title":"Deciphering the transcriptional histone acetylation code for a human gene","volume":"111","author":"Agalioti","year":"2002","journal-title":"Cell"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0002","first-page":"S52","article-title":"Histone deacetylation inhibitors","volume":"1","author":"Ardizzoni","year":"2002","journal-title":"Suppl. Tumori"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0003","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.2174\/0929867033456657","article-title":"Histone deacetylase inhibitors: From chromatin remodeling to experimental cancer therapeutics","volume":"10","author":"Arts","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0004","doi-asserted-by":"crossref","first-page":"17625","DOI":"10.1074\/jbc.M301646200","article-title":"Direct interaction of Ca2+\u29f8calmodulin inhibits histone deacetylase 5 repressor core binding to myocyte enhancer factor 2","volume":"278","author":"Berger","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0005","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00001813-200209000-00013","article-title":"Antineoplastic action of 5-aza-2\u2032-deoxycytidine and phenylbutyrate on human lung carcinoma cells","volume":"13","author":"Boivin","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0006","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2174\/0929867033456585","article-title":"Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: Synthesis and antiproliferative evaluation","volume":"10","author":"Bouchain","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0007","first-page":"5165","article-title":"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo","volume":"60","author":"Butler","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0008","first-page":"962","article-title":"Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase","volume":"7","author":"Butler","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0009","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1073\/pnas.182372299","article-title":"The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin","volume":"99","author":"Butler","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0010","first-page":"3972","article-title":"Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacologic evaluation of intravenous and oral PB","volume":"17","author":"Carducci","year":"1997","journal-title":"Anticancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0011","first-page":"379","article-title":"Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate","volume":"2","author":"Carducci","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0012","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/35083062","article-title":"Acetylation control of the retinoblastoma tumour-suppressor protein","volume":"3","author":"Chan","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0013","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.1999.17.3.984","article-title":"Phase II study of phenylacetate in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report","volume":"17","author":"Chang","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0014","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1349-7006.2001.tb02153.x","article-title":"Expression profile of histone deacetylase 1 in gastric cancer tissues","volume":"92","author":"Choi","year":"2001","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0015","first-page":"3591","article-title":"The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans-retinoic acid","volume":"61","author":"Coffey","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0960-894X(00)00604-1","article-title":"Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure\u2013activity relationships of apicidin. Part 1","volume":"11","author":"Colletti","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0960-894X(00)00605-3","article-title":"Broad spectrum antiprotozoal agents that inhibit histone deacetylase: Structure\u2013activity relationships of apicidin. Part 2","volume":"11","author":"Colletti","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7","article-title":"Histone deacetylases, transcriptional control, and cancer","volume":"184","author":"Cress","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0019","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.2174\/0929867033456576","article-title":"Histone deacetylase inhibitors: The Abbott experience","volume":"10","author":"Curtin","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0020","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1073\/pnas.0337639100","article-title":"Regulation of peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1 (PGC-1\u03b1) and mitochondrial function by MEF2 and HDAC5","volume":"100","author":"Czubryt","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0021","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1074-7613(03)00109-2","article-title":"HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis","volume":"18","author":"Dequiedt","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0022","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0023","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): Characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0024","article-title":"Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma","author":"Duvic","year":"2003"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/(SICI)1097-4644(1998)72:30\/31+<194::AID-JCB24>3.0.CO;2-H","article-title":"Role of histone deacetylases in acute leukemia","volume":"30\u201331","author":"Fenrick","year":"1998","journal-title":"J. Cell. Biochem. Suppl."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0026","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0027","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1074\/jbc.M108055200","article-title":"Isolation and characterization of a novel class II histone deacetylase, HDAC10","volume":"277","author":"Fischer","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0028","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature02017","article-title":"Binary switches and modification cassettes in histone biology and beyond","volume":"425","author":"Fischle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0029","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/S0960-894X(02)00754-0","article-title":"Trifluoromethyl ketones as inhibitors of histone deacetylase","volume":"12","author":"Frey","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1073\/pnas.98.1.87","article-title":"Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin","volume":"98","author":"Furumai","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0031","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0032","doi-asserted-by":"crossref","first-page":"19618","DOI":"10.1074\/jbc.M201174200","article-title":"Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions","volume":"277","author":"Galasinski","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0033","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0034","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/73536","article-title":"Mutations truncating the EP300 acetylase in human cancers","volume":"24","author":"Gayther","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0035","first-page":"2292","article-title":"A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies","volume":"7","author":"Gilbert","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0036","first-page":"87a","article-title":"Methyltransferase (MT) activity and gene expression in tumor biopsies from patients enrolled in a phase I study of the MT inhibitor, 5-azacytidine and histone deacetylase inhibitor, phenylbutyrate in refractory solid tumors","volume":"20","author":"Gilbert","year":"2001","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0037","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0168-9525(98)01438-3","article-title":"Conjunction dysfunction: CBP\u29f8p300 in human disease","volume":"14","author":"Giles","year":"1998","journal-title":"Trends Genet."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0038","first-page":"151","article-title":"Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines","volume":"2","author":"Glaser","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0039","first-page":"3938a","article-title":"Clinical development of sodium phenylbutyrate as putative differentiating agent in myeloid malignancies","volume":"17","author":"Gore","year":"1997","journal-title":"Anticancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0040","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0041","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/excr.2000.5080","article-title":"The human histone deacetylase family","volume":"262","author":"Gray","year":"2001","journal-title":"Exp. Cell Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0042","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone deacetylase inhibitor activation of p21WAF1 involves changes in promoter associated proteins, including HDAC1","volume":"101","author":"Gui","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0043","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0044","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1128\/MCB.22.22.7820-7830.2002","article-title":"Activation of the mouse histone deacetylase 1 gene by cooperative histone phosphorylation and acetylation","volume":"22","author":"Hauser","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0045","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1172\/JCI200111537","article-title":"Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia","volume":"108","author":"He","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0046","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0047","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/MCB.23.15.5122-5131.2003","article-title":"The N-CoR\u29f8histone deacetylase 3 complex is required for repression by thyroid hormone receptor","volume":"23","author":"Ishizuka","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0048","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0049","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","article-title":"Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?","volume":"4","author":"Johnstone","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0051","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ijc.11403","article-title":"Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor \u03b1","volume":"107","author":"Kawai","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0052","first-page":"18","article-title":"Pivanex activity in refractory non-small cell lung cancer, a phase II study","author":"Keer","year":"2001"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0053","article-title":"A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor of suberoylanilide hydroxamic acid (SAHA)","author":"Kelly","year":"2002"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0054","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1517\/13543784.11.12.1695","article-title":"Histone deacetylase inhibitors: From target to clinical trials","volume":"11","author":"Kelly","year":"2002","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0055","article-title":"Phase I clinical trial of an oral histone deacetylase inhibitor: Suberoylanilide hydroxamic acid (SAHA)","author":"Kelly","year":"2003"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0056","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0057","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0959-437X(00)00174-X","article-title":"Functional significance of histone deacetylase diversity","volume":"11","author":"Khochbin","year":"2001","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0058","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/86507","article-title":"Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes","volume":"7","author":"Kim","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0059","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1038\/sj.onc.1202564","article-title":"Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase","volume":"18","author":"Kim","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0060","first-page":"18","article-title":"Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumors","author":"Kimmel","year":"2001"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0061","first-page":"4459","article-title":"Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity","volume":"61","author":"Komatsu","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0062","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/emboj\/19.6.1176","article-title":"Acetylation: A regulatory modification to rival phosphorylation?","volume":"19","author":"Kouzarides","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0063","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ijc.1602","article-title":"Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis","volume":"97","author":"Kwon","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0064","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1007\/s00018-003-3090-z","article-title":"Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases","volume":"60","author":"Kyrylenko","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0065","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0955-0674(02)00335-6","article-title":"The many faces of histone lysine methylation","volume":"14","author":"Lachner","year":"2002","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0066","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/emboj\/21.11.2672","article-title":"Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression","volume":"21","author":"Lagger","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0067","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1128\/MCB.23.8.2669-2679.2003","article-title":"The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21\u29f8WAF1\u29f8CIP1 gene","volume":"23","author":"Lagger","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0068","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-230X(02)86002-X","article-title":"Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation","volume":"86","author":"Lehrmann","year":"2002","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0069","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/38444","article-title":"Crystal structure of the nucleosome core particle at 2.8 \u00c5 resolution","volume":"389","author":"Luger","year":"1997","journal-title":"Nature"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0070","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/35410","article-title":"Retinoblastoma protein represses transcription by recruiting a histone deacetylase","volume":"391","author":"Magnaghi-Jaulin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0071","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1073\/pnas.0437843100","article-title":"MyoD is functionally linked to the silencing of a muscle-specific regulatory gene prior to skeletal myogenesis","volume":"100","author":"Mal","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0072","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: Causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0073","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1471-4892(03)00084-5","article-title":"Histone deacetylases","volume":"3","author":"Marks","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0074","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1093\/emboj\/cdf682","article-title":"In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation","volume":"21","author":"Matsuyama","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0075","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1095\/biolreprod.102.005991","article-title":"Quantification of histone acetyltransferase and histone deacetylase transcripts during early bovine embryo development","volume":"68","author":"McGraw","year":"2003","journal-title":"Biol. Reprod."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0076","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0959-437X(00)00224-0","article-title":"Control of muscle development by dueling HATs and HDACs","volume":"11","author":"McKinsey","year":"2001","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0077","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0955-0674(02)00389-7","article-title":"Signaling chromatin to make muscle","volume":"14","author":"McKinsey","year":"2002","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0078","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0079","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/hmg\/10.10.1071","article-title":"Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein\u2013Taybi syndrome","volume":"10","author":"Murata","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0080","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1101\/gad.13.19.2490","article-title":"Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a","volume":"13","author":"Murphy","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0081","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S1357-2725(02)00079-1","article-title":"Senescence and epigenetic dysregulation in cancer","volume":"34","author":"Neumeister","year":"2002","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0082","article-title":"Phase I pharmacokinetic study of CI-994 in combination with carboplatin and paclitaxel in patients with advanced solid tumors","author":"Olivares","year":"2001"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0083","doi-asserted-by":"crossref","first-page":"16059","DOI":"10.1074\/jbc.M212935200","article-title":"The histone deacetylase 9 gene encodes multiple protein isoforms","volume":"278","author":"Petrie","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0084","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0085","first-page":"18","article-title":"Histone deacetylase inhibitor for the treatment of peripheral or cutaneous T-cell lymphoma","author":"Piekarz","year":"2001"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0086","article-title":"Cardiac effects of depsipeptide, FK228, in patients with T-cell lymphomas","author":"Piekarz","year":"2003"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0087","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2002-3-5-reviews0006","article-title":"The diversity of acetylated proteins","volume":"3","author":"Polevoda","year":"2002","journal-title":"Genome Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0088","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006489328324","article-title":"Chronic oral administration of CI-994: A phase 1 study","volume":"19","author":"Prakash","year":"2001","journal-title":"Investig. New Drugs"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0089","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/sj.bjc.6690493","article-title":"Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate","volume":"80","author":"Qiu","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0090","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1128\/MCB.23.12.4162-4173.2003","article-title":"Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5","volume":"23","author":"Rascle","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0091","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1471-4892(02)00178-9","article-title":"Using cancer genetics to guide the selection of anticancer drug targets","volume":"2","author":"Reddy","year":"2002","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0092","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2174\/0929867033456675","article-title":"The discovery of NVP-LAQ824: From concept to clinic","volume":"10","author":"Remiszewski","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0093","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0092-8674(02)00644-X","article-title":"Epigenetic codes for heterochromatin formation and silencing: Rounding up the usual suspects","volume":"108","author":"Richards","year":"2002","journal-title":"Cell"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0094","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1073\/pnas.93.12.5705","article-title":"Second generation hybrid polar compounds are potent inducers of transformed cell differentiation","volume":"93","author":"Richon","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0095","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1073\/pnas.95.6.3003","article-title":"A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases","volume":"95","author":"Richon","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0096","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0097","article-title":"A phase I trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients","author":"Ryan","year":"2003"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0098","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.96.8.4592","article-title":"A synthetic inhibitor of histone deacetylase, MS-27\u2013275, with marked in vivo antitumor activity against human tumors","volume":"96","author":"Saito","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0099","first-page":"718","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms","volume":"8","author":"Sandor","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0100","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/MCB.23.19.6993-7004.2003","article-title":"Autoregulation of mouse histone deacetylase 1 expression","volume":"23","author":"Schuettengruber","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0101","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/jo016088w","article-title":"Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal \u03b1-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities","volume":"67","author":"Singh","year":"2002","journal-title":"J. Org. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0102","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2002-07-2073","article-title":"Histone deacetylase inhibitors: A new class of immunosuppressors targeting a novel signal-pathway essential for CD154 expression","volume":"101","author":"Skov","year":"2003","journal-title":"Blood"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0103","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/viro.1999.0181","article-title":"Association of histone deacetylase with COUP-TF in tumorigenic Ad12-transformed cells and its potential role in shut-off of MHC class I transcription","volume":"268","author":"Smirnov","year":"2000","journal-title":"Virology"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0104","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1172\/JCI0216547","article-title":"An increasingly complex code","volume":"110","author":"Spotswood","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0105","first-page":"3137","article-title":"A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library","volume":"60","author":"Su","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0106","first-page":"1690","article-title":"A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer","volume":"54","author":"Thibault","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0107","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1002\/1097-0142(19950615)75:12<2932::AID-CNCR2820751221>3.0.CO;2-P","article-title":"Phase I study of phenylacetate administered twice daily to patients with cancer","volume":"75","author":"Thibault","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0108","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/PL00000896","article-title":"Histone acetylation and disease","volume":"58","author":"Timmermann","year":"2001","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0109","first-page":"333","article-title":"Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma","volume":"10","author":"Toh","year":"2003","journal-title":"Oncol. Rep."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0110","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/nar\/30.5.1114","article-title":"Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain","volume":"30","author":"Tong","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0111","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1093\/nar\/gkg473","article-title":"Histone deacetylases in fungi: Novel members, new facts","volume":"31","author":"Trojer","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0112","doi-asserted-by":"crossref","first-page":"31826","DOI":"10.1074\/jbc.M204149200","article-title":"Regulation of histone deacetylase 2 by protein kinase CK2","volume":"277","author":"Tsai","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0113","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1093\/emboj\/19.15.4074","article-title":"Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway","volume":"19","author":"Urnov","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0114","first-page":"245","article-title":"The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation","volume":"5","author":"Van Lint","year":"1996","journal-title":"Gene Expr."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0115","first-page":"87","article-title":"Cloning and structural characterization of the human histone deacetylase 6 gene","volume":"12","author":"Voelter-Mahlknecht","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0116","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1038\/sj.onc.1203176","article-title":"Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2\u29f8Bcl-XL, c-Jun, and p21CIP1, but independent of p53","volume":"18","author":"Vrana","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0117","doi-asserted-by":"crossref","first-page":"D610","DOI":"10.2741\/1wang1","article-title":"Histone acetylation and the cell-cycle in cancer","volume":"6","author":"Wang","year":"2001","journal-title":"Front. Biosci."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0118","doi-asserted-by":"crossref","first-page":"10860","DOI":"10.1073\/pnas.95.18.10860","article-title":"ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR\u29f8mSin3\u29f8HDAC1 complex","volume":"95","author":"Wang","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0119","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/jnci\/90.21.1621","article-title":"Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase","volume":"90","author":"Warrell","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0120","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1096\/fj.02-1003fje","article-title":"Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints","volume":"17","author":"Warrener","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0121","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1139\/o02-080","article-title":"Dynamics of histone acetylation in vivo: A function for acetylation turnover?","volume":"80","author":"Waterborg","year":"2002","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0122","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1074\/jbc.M206528200","article-title":"Histone deacetylase 3 binds to and regulates the multifunctional transcription factor TFII-I","volume":"278","author":"Wen","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0123","first-page":"87a","article-title":"A phase I study of an oral histone deacetylase inhibitor, MS-275 in patients with refractory solid tumors and lymphomas","author":"Wisinski","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0124","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0168-9525(96)81401-6","article-title":"Deviant nucleosomes: The functional specialization of chromatin","volume":"12","author":"Wolffe","year":"1996","journal-title":"Trends Genet."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0125","first-page":"487a","article-title":"Phase II trial of CI-994 in patients with advanced nonsmall cell lung cancer","volume":"18","author":"Wozniak","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0126","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/MCB.23.3.1025-1033.2003","article-title":"Interaction of histone acetylases and deacetylases in vivo","volume":"23","author":"Yamagoe","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0127","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1073\/pnas.96.9.4983","article-title":"BRCA1 interacts with components of the histone deacetylase complex","volume":"96","author":"Yarden","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0128","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/emboj\/cdg120","article-title":"Purification and functional characterization of the human N-CoR complex: The roles of HDAC3, TBL1 and TBLR1","volume":"22","author":"Yoon","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0129","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","article-title":"Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A","volume":"265","author":"Yoshida","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0130","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2174\/0929867033456602","article-title":"From discovery to the coming generation of histone deacetylase inhibitors","volume":"10","author":"Yoshida","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0131","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/jnci\/94.7.504","article-title":"Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228","volume":"94","author":"Yu","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0132","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1101\/gad.927301","article-title":"Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails","volume":"15","author":"Zhang","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0133","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/emboj\/cdg115","article-title":"HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo","volume":"22","author":"Zhang","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0134","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/blood.V99.4.1356","article-title":"Frequent mutations in the ligand-binding domain of PML-RAR\u03b1 after multiple relapses of acute promyelocytic leukemia: Analysis for functional relationship to response to all-trans-retinoic acid and histone deacetylase inhibitors in vitro and in vivo","volume":"99","author":"Zhou","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0065-230X(04)91004-4_BIB.0135","doi-asserted-by":"crossref","first-page":"14329","DOI":"10.1073\/pnas.250494697","article-title":"Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras","volume":"97","author":"Zhou","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Advances in Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X04910044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X04910044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:31:08Z","timestamp":1758738668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X04910044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"ISBN":["9780120066919"],"references-count":135,"URL":"https:\/\/doi.org\/10.1016\/s0065-230x(04)91004-4","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2004]]}}}